Cow vigilantes get thrashed after intercepting vehicle

Bengaluru, Feb 7: The Bruhat Bengaluru Mahanagara Palike (BBMP) ordered the destruction of a tilted building in the city after evacuating about 150 people from 35 families in the vicinity, an official said on Thursday.

"The top portion of the building has been destroyed 70 per cent today (Thursday). Later, the destruction contractor will allow machines to be used," Bruhat Bengaluru Mahanagara Palike (BBMP) Yelahanka joint commissioner Ashok said.

Located on Vinayaknagar Street in Hebbal's Kempapura, the five-storey building being used as a hostel for boys got tilted on Wednesday morning, spreading panic in the neighbourhood.

Though the tilted building owned by one Rahul, a jeweller, was a sound structure, Ashok said a neighbour, Babu, hired a JCB excavator to dig deep beside the affected structure to build his own structure.

"Babu not only dug very deep but also damaged the foundation pillar of the tilted building, weakening the structure and leading to its slant," said Ashok.

Babu has been booked and arrested even as the police are on the look-out for the JCB owner and operator.

The titled building erected five floors unauthorisedly and falls into the B Khata category. It was constructed without the civic body's plan, said Ashok. 

A Khata and B Khata denote the two types of khatas that exist under BBMP. Khata is a document which shows a property owner having an account with the municipality to pay taxes. An A Khata denotes that the building owner has paid relevant property taxes and that the building conforms to building bylaws and government rules. A B Khata denotes that the building is in violation of government regulations regarding properties in Bengaluru, even when the civic charges for the property have been cleared by the owner.

"As per procedure, we issue notice, but such constructions are rampant in the city. Under the BBMP jurisdiction, there are 15 lakh B Khata structures," said Ashok.

For all B Khata sites, the civic body does not give any plan and there is no proper control on them, he said.

Ashok said the case to regularise the B Khata buildings to A Khata buildings is currently pending in the Supreme Court.

Luckily, no injury or loss of life has been reported from the tilted building.

The civic body arranged alternative accommodation for the affected families, but most of them chose to stay with their relatives, said Ashok.

Mangaluru, Feb 8: Professional services company Cognizant on Friday opened a new facility in Mangaluru, expanding its presence in Karnataka. Located in the heart of the city, the new 100,000 sq- ft facility can accommodate more than 1,100 employees, the NASDAQ-listed company said in a statement.

Cognizant has had an association with Mangaluru since 2011 when it acquired CoreLogic Global Services Private Limited (CoreLogic India), the India-based captive operations of CoreLogic, one of the largest real estate information and analytics provider in the US market.

From its existing centre in Mangaluru, Cognizant provides consulting, enterprise applications and business process services in the area of mortgage processing covering property taxes, research and investigations, property data warehousing and management of geospatial data.

The company currently employs more than 600 professionals in Mangaluru, more than 50 per cent of whom are women.

In addition to experienced professionals, Cognizant also hires fresh graduates for its Mangaluru centre from leading institutions such as Sahyadari Institute of Technology and Management, Manipal Institute of Technology, N.M.A.M. Institute of Technology, St Joseph's College of Engineering, Canara Engineering College, N.I.T.K. Surathkal, PA College of Engineering and Srinivas College of Engineering, as mortgage origination and servicing specialists, business analysts, consultants, automation specialists and software engineers.

In Karnataka, Cognizant also has operations in Bengaluru and Mysuru. The company has more than 28,000 professionals in Bengaluru and nearly 700 professionals in Mysuru.

States and union territories of India, Service companies, Rail transport in Karnataka, Cognizant, Dun & Bradstreet, Teaneck, New Jersey,Transport in Karnataka, Transport in Mangalore, Mangalore, Karnataka, Udupi railway station, Mangalore Junction railway station, St Joseph's College of Engineering, Sahyadari Institute of Technology, CoreLogic Global Services Private Limited, Canara Engineering College, Srinivas College of Engineering,real estate information, PA College of Engineering, N.M.A.M. Institute of Technology, st joseph's, N.I.T.K. Surathkal, Manipal Institute of Technology, software engineers, United States, business process services, mortgage processing, Institute of Technology

The United States of America has bought almost the entire world's supply of remdesivir, one of just two drugs proven to treat COVID-19. 

“President Trump has struck an amazing deal to ensure Americans have access to the first authorised therapeutic for Covid-19,” said the US health and human services secretary, Alex Azar. 

“To the extent possible, we want to ensure that any American patient who needs remdesivir can get it. The Trump administration is doing everything in our power to learn more about life-saving therapeutics for Covid-19 and secure access to these options for the American people.”

The announcement implies that no other country in the world will be able to buy remdesivir for next three months at least.

The anti-viral drug patented by the US-based Gilead biotech firm is the only one approved by the European Medicines Agency (EMA) to treat patients with the novel coronavirus.

The Trump administration has already shown that it is prepared to outbid and outmanoeuvre all other countries to secure the medical supplies it needs for the US.

“They’ve got access to most of the drug supply [of remdesivir], so there’s nothing for Europe,” said Dr Andrew Hill, senior visiting research fellow at Liverpool University.

Remdesivir, the first drug approved by licensing authorities in the US to treat Covid-19, is made by Gilead and has been shown to help people recover faster from the disease. 

The first 140,000 doses, supplied to drug trials around the world, have been used up. The Trump administration has now bought more than 500,000 doses, which is all of Gilead’s production for July and 90% of August and September.